IP Receptor
Novel IP Receptor Agonist CS585
Drug candidate CS585 is a highly potent, oral and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. In preclinical studies, CS585 has demonstrated efficacy through potent and selective stimulation of the prostacyclin (IP) receptor, showing the ability to prevent thrombosis without an associated increased risk of bleeding. CS585 is currently undergoing preclinical evaluation.
Preclinical data suggest that CS585 provides a new option of activating the IP receptor to decrease platelet reactivity and could represent the first viable option for targeting the IP-receptor on platelets for inhibition of thrombosis with a reduced risk of bleeding. The preclinical results with CS585, including a head-to-head comparison of CS585 and the FDA-approved IP receptor agonists selexipag and iloprost, indicate a favorable profile for inhibiting platelet activation and clot formation. CS585 was shown to be more selective and have a more sustained efficacy than the currently available IP receptor agonists. CS585 also demonstrated a sustained duration of action in mice in the ability to inhibit platelet activation through several routes of administration including oral.
The growing body of evidence around drug candidate CS585 supports favorable tolerability and efficacy in preclinical studies. Recently, the early results from CS585 were published in the top-tier journal Blood showing that CS585 is a highly potent and selective compound given both orally and intravenously and prevents thrombosis for up to 48 hours as observed in preclinical studies. Following the publication, a commentary article and the Blood Podcast highlighted that the new preclinical findings of CS585 could be a significant milestone to improve anti-thrombotic treatment strategies without bleeding.
A license agreement for drug candidate CS585 with the University of Michigan provides Cereno exclusive rights to further development and commercialization of CS585.
Collaboration
Research collaboration with the University of Michigan
The University of Michigan, located in Ann Arbor, Michigan, USA, is a leading public research institution renowned for its successful collaborations with the pharmaceutical industry. Prof. Michael Holinstat, an esteemed pharmacologist with a PhD from the University of Illinois in Chicago, heads Cereno's preclinical work at the University. He also serves as a Professor in the Department of Pharmacology, the Department of Internal Medicine (Division of Cardiovascular Medicine), and the Department of Vascular Surgery at the University of Michigan, leading translational programs in drug development for hemostasis and thrombosis. Prof. Holinstat's extensive research spans thrombosis, pharmacology, and hematology, and he has established a cutting-edge laboratory for studying pharmacological effects on platelets and coagulation, both in vitro and in vivo.
Updated August 2025.